Monte Rosa Therapeutics, Inc. (GLUE) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Monte Rosa Therapeutics, Inc.
Address
321 Harrison Avenue
Boston, MA 02118
United States of America (the)
Phone
617 949 2643
Website
Sector
Healthcare
Industry
Biotechnology
Employees
173
First IPO Date
June 24, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Markus Warmuth | President, Chief Executive Officer & Director | 1.08M | 1971 |
| Sharon Townson | Chief Scientific Officer | 644,600 | 1975 |
| Filip Janku | Chief Medical Officer | 833,600 | 1974 |
| Phil Nickson | Chief Business & Legal Officer | 833,600 | 1979 |
| John C. Castle | Chief Data & Information Officer | 0 | 1971 |
| Andrew Funderburk | Chief Investor Relations and Strategy Officer | 0 | N/A |
| Magnus Walter DPHIL | Chief Technology Officer | 0 | N/A |
| Matthew Bowen | Corporate Controller & Principal Accounting Officer | 0 | 1989 |
| Jennifer Champoux | Chief Operating Officer | 0 | 1972 |
Description
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
